Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2605-2612

  Hung, Tsui Lien ^a   Chen, Fen Fen ^a   Liu, Jacqueline M ^b   Lai, Wu Wei ^a   Hsiao, Al Li ^a   Huang, Wen Tsung ^a   Chen, Helen H W ^a   Su, Wu Chou ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; ONCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL ANALYSIS;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KERATINS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PLEURAL EFFUSION; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0037479817     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Memon, A. N., and Zawadzki, G. A. Pleural effusions. Cur. Prob. Cancer, 5: 3-30, 1981.
2. Anderson, C. B., Philpott, G. W., and Ferguson, T. B. The treatment of malignant pleural effusions. Cancer (Phila.), 33: 916-922, 1974.
3. Sugiura, S., Ando, Y., Minami, H., Ando, M., Sakai, S., and Shimokata, K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin. Cancer Res., 3: 47-50, 1997.
4. Naito, T., Satoh, H., Ishikawa, H., Yamashita, Y. T., Kamma, H., Takahashi, H., Ohtsuka, M., and Hasegawa, S. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res., 17: 4743-4746, 1997.
5. Hoffman, P. C., Mauer, A. M., and Vokes, E. E. Lung cancer. Lancet, 355: 479-485, 2000.
6. Chang, S. C., Lee, L. N., Kuo, S. H., Luh, K. T., and Wu, S. C. Survival of patients with malignant pleural effusion (in Chinese). J. Formos. Med. Assoc., 86: 672-678, 1987.
7. Yang, S. P., Luh, K. T., Kuo, S. H., and Lin, C. C. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration: a 30-year consecutive study. Jpn. J. Clin. Oncol., 14: 7-19, 1984.
8. Hynes, N. E., and Stem, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
9. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
10. Weiner, D. B., Nordberg, J., Robinson, R., Nowell, P. C., Gazdar, A., Greene, M. I., Williams, W. V., Cohen, J. A., and Kem, J. A. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res., 50: 421-425, 1990.
11. Kem, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Greene, M. I., Tomey, L., and Robinson, R. A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184-5187, 1990.
12. Pastorino, U., Andreola, S., Tagliabue, E., Pezzella, F., Incarbone, M., Sozzi, G., Buyse, M., Menard, S., Pierotti, M., and Rilke, F. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol., 15: 2858-2865, 1997.
13. Yu, D., Wang, S. S., Dulski, K. M., Tsai, C. M., Nicolson, G. L., and Hung, M. C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res., 54: 3260-3266, 1994.
14. Tsai, C. M., Chang, K. T., Perng, R. P., Mitsudomi, T., Chen, M. H., Kadoyama, C., and Gazdar, A. F. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst. (Bethesda), 85: 897-901, 1993.
15. Marel, M., Stastny, B., Melinova, L., Svandova, E., and Light, R. W. Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest, 107: 1598-1603, 1995.
16. Prakash, B. S., and Reiman, H. M. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin. Proc., 60: 158-164, 1985.
17. Ferrer, J., Villarino, M. A., Encabo, G., Felip, E., Bermejo, B., Vila, S., and Orriols, R. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer (Phila.), 86: 1488-1495, 1999.
18. Miedouge, M., Rouzaud, P., Salama, G., Pujazon, M. C., Vincent, C., Mauduyt, M. A., Reyre, J., Carles, P., and Serre, G. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br. J. Cancer, 81: 1059-1065, 1999.
19. Ebert, W., Dienemann, H., Fateh-Moghadam, A., Scheulen, M., Konietzko, N., Schleich, T., and Bombardieri, E. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur. J. Clin. Chem. Clin. Biochem., 32: 189-199, 1994.
20. Wieskopf, B., Demangeat, C., Purohit, A., Stenger, R., Gries, P., Kreisman, H., and Quoix, E. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest, 108: 163-169, 1995.
21. Satoh, H., Sumi, M., Yagyu, H., Ishikawa, H., Suyama, T., Naitoh, T., Saitoh, T., and Hasegawa, S. Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. Oncology, 52: 211-214, 1995.
22. Toumbis, M., Rasidakis, A., Passalidou, E., Kalomenidis, J., Alchanatis, M., Orphanidou, D., and Jordanoglou, J. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res., 16: 2101-2104, 1996.
23. Giatromanolaki, A., Gorgoulis, V., Chetty, R., Koukourakis, M. I., Whitehouse, R., Kittas, C., Veslemes, M., Gatter, K. C., and Iordanoglou, I. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res., 16: 987-993, 1996.
24. Camp, R. L., Rimm, E. B., and Rimm, D. L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer (Phila.), 86: 2259-2265, 1999.
25. Krouwer, J. S. Cumulative distribution analysis graphs: an alternative to ROC curves. Clin. Chem., 33: 2305-2306, 1987.
26. Tsai, C. M., Chang, K. T., Wu, L. H., Chen, J. Y., Gazdar, A. F., Mitsudomi, T., Chen, M. H., and Pemg, R. P. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res., 56: 206-209, 1996.
27. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S., and Sugimachi, K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer, 27: 1372-1375, 1991.
28. Harpole, D. H., Herndon, J. E., Wolfe, W. G., Iglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51-56, 1995.
29. Fontanini, G., De Laurentiis, M., Vignati, S., Chine, S., Lucchi, M., Silvestri, V., Mussi, A., De Placido., S., Tortora, G., Bianco, A. R., Gullick, W., Angeletti, C. A., Bevilacqua, G., and Ciardiello, F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res., 4: 241-249, 1998.
30. Hirsch, F. R., Varella-Garcia, M., Franklin, W. A., Veve, R., Chen, L., Helfrich, B., Zeng, C., Baron, A., and Bunn, P. A., Jr. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer, 86: 1449-1456, 2002.
31. Shiraishi, M., Noguchi, M., Shimosato, Y., and Sekiya, T. Amplification of proto-oncogenes in surgical specimens of human lung carcinomas. Cancer Res., 49: 6474-6479, 1989.
32. Harpole, D. H., Jr., Marks, J. R., Richards, W. G., Herndon, J. E., II, and Sugarbaker, D. J. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin. Cancer Res., 1: 659-664, 1995.
33. Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D., Holscher, A. H., and Danenberg, P. V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res., 7: 1850-1855, 2001.
34. Beer, D. G., Kardia, S. L., Huang, C. C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., Lizyness, M. L., Kuick, R., Hayasaka, S., Taylor, J. M., Iannettoni, M. D., Orringer, M. B., and Hanash, S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med., 8: 816-824, 2002.
35. Moldvay, J., Scheid, P., Wild, P., Nabil, K., Siat, J., Borrelly, J., Marie, B., Farre, G., Labib, T., Pottier, G., Sesboue, R., Bronner, C., Vignaud, J. M., Martinet, Y., and Martinet, N. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin. Cancer Res., 6: 1125-1134, 2000.
36. Pfeiffer, P., Clausen, P. P., Andersen, K., and Rose, C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br. J. Cancer, 74: 86-91, 1996.
37. Simon, R., Nocito, A., Hubscher, T., Bucher, C., Torhorst, J., Schraml, P., Bubendorf, L., Mihatsch, M. M., Moch, H., Wilber, K., Schotzau, A., Kononen, J., and Sauter, G. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl. Cancer Inst. (Bethesda), 93: 1141-1146, 2001.
38. Pupa, S. M., Menard, S., Morelli, D., Pozzi, B., De Palo, G., and Colnaghi, M. I. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8: 2917-2923, 1993.
39. Osaki, T., Mitsudomi, T., Oyama, T., Nakanishi, R., and Yasumoto, K. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest, 108: 157-162, 1995.
40. Ardizzoni, A., Cafferata, M. A., Paganuzzi, M., Filiberti, R., Marroni, P., Neri, M., Fontana, V., Nicolo, G., Perdelli, L., Stampino, C. G., Rosso, R., and Puntoni, R. Study of pretreatment serum levels of Her-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced non-small cell lung carcinoma. Cancer (Phila.), 92: 1896-1904, 2001.
41. Heinmoeller, P., Gross, C., Schmidtgen, C., Beyser, K., Nordhoff, C., Bockholt, A., Pedrocchi, M., Rueschoff, J., and Kassel, K. HER2 status in non-small cell lung cancer (NSCLC): results from the patient screening for enrolment to a Phase 2 study of Herceptin. Eur. J. Cancer, 37 (Suppl. 6): 50, 2001.
42. Sugano, K., Ushiama, M., Fukutomi, T., Tsuda, H., Kitoh, T., and Ohkura, H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int. J. Cancer, 89: 329-336, 2000.